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ABSTRACT  
Transport of intracellular cargo is an important and dynamic process required for 
cell maintenance and survival. Dynein is the motor protein that carries organelles and 
vesicles from the cell periphery to the cell center along the microtubule network. 
Dynactin is a protein that activates dynein for this transport process. Together, dynein 
and dynactin forms a motor protein complex that is essential for transport processes in all 
the vertebrate cells. Using fluorescent microscope based live cell imaging techniques and 
kymograph analyses, I studied dynein/dynactin disruptions on the intracellular transport 
in two different cell systems. In one set of experiments, effects of dynein heavy chain 
(DHC) mutations on the vesicular motility were characterized in the fungus model system 
Neurospora crassa. I found that many DHC mutations had a severe transport defect, 
while one mutation linked to neurodegeneration in mice had a subtle effect on 
intracellular transport of vesicles. In a different set of experiments in mammalian tissue 
culture CAD cells, I studied the effects of dynactin knockdown and dynein inhibition on 
mitochondrial motility. My results indicated that reductions in dynactin levels decrease 
the average number of mitochondrial movements and surprisingly, increase the 
mitochondrial run lengths. Also, I determined that the dynein inhibitory drug Ciliobrevin 
causes changes in mitochondrial morphology and decreases the number of mitochondrial 
movements inside cells. Overall, my research shows that distinct disruptions in the 
dynein and dynactin motor complex alters intracellular motility, but in different ways. So 
far, my studies have set the ground work for future experiments to analyze the motility 
mechanism of motor proteins having mutations that lead to neurodegenerative disorders.  
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CHAPTER 1: INTRODUCTION 
Cells have to transport essential cargoes (such as organelles, vesicles, signal 
peptides, hormones) to maintain their health and to survive. Cytoskeletal motor proteins 
help in the transport of these cargoes using an extensive microtubule network inside the 
cell. The minus ends of the microtubule are capped near the MTOC and the plus end of 
microtubules extends outward towards the cell periphery (Fig. 1). Plus end directed motor 
proteins (kinesin) carry cargo from the cell center towards the cell periphery (Fig.1). In 
contrast, the minus end directed motor protein dynein carries cargo from the cell 
periphery to the cell center (Paschal and Vallee, 1987).  
 
Figure 1: Microtubule based cytoskeleton inside a cell 
Motor proteins (dynein and kinesin) carry cargo (blue vesicles) on a microtubule (MT) network 
inside a cell. The plus and minus signs denote the respective ends of MT. The arrows show the 
direction of the moving motor proteins. 
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A complicated system of motor protein involvement is needed to keep the robust 
transport system functioning inside cells. In some cases, a cargo might have two opposite 
motor proteins attached (Fig.1), of which only one motor protein (i.e. kinesin) can be 
active. In this case, the active kinesin carries the cargo towards the plus end of a 
microtubule. In the same cell, motor recycling happens that allows dynein to be recycled 
back to the plus end of the microtubule by kinesin. Consequently, dynein can bind to 
cargoes at the plus ends and carry them towards the minus ends of the microtubules. 
Other possibilities include having both kinesin and dynein active and attached on the 
same cargo (Fig.1, mitochondria shown). In such cases there could be a “tug-of-war” 
between the two opposite end directed motor proteins. Whichever motor protein manages 
to move can carry the cargo in the respective direction on the microtubule. For example, 
in the “tug-of-war” situation if dynein is active, then it will carry the cargo towards the 
minus end of the microtubule.  
1.1 Role of the dynein-dynactin motor protein complex in transport 
The motor protein dynein cleaves ATP and generates force to “walk” on the 
microtubule in a hand over hand fashion. During dynein’s mechanochemical cycle, the 
ATP binds to the ATPase domains of dynein and gets hydrolyzed to ADP + Pi. The 
binding of ATP, its hydrolysis, and the subsequent release of products cause subsequent 
conformational changes in the dynein molecule. During this cycle, dynein’s microtubule 
binding stalk is thought to change angle with respect to the rest of the molecule, which 
makes the MT binding stalks release or bind the microtubule (Gennerich and Vale, 2009). 
By taking sequential steps in the mechanochemical cycle, one head of the motor protein 
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takes a step forward and then binds to the next binding site on the microtubule. A dynein 
molecule alternates its globular heads while taking steps on the microtubule, as one of the 
heads has to maintain contact with the microtubule to avoid its accidental release into the 
cytoplasm. Ultimately, dynein does release both of its globular head from the microtubule 
to effectively terminate the transport event.  
 
Figure 2: The dynein/dynactin motor complex 
The model here shows how the dynein and dynactin molecules interact together to form a motor 
protein complex. This dynein/dynactin complex then carries the cargo on a microtubule, towards 
its minus ends. Dynactin helps in loading the cargo onto the dynein molecule by functioning as a 
cargo adaptor. Dynactin also maintains a contact with the microtubule by acting as a secondary 
linkage/molecular tether for the motor protein complex. 
 
Dynein also interacts with its molecular activator dynactin (Fig.2) to form a motor 
protein complex. Dynactin acts a molecular tether (King and Schroer, 2000) to help 
dynein stay on the microtubule to continue the transport event in case dynein lets go of 
both of its globular heads. Hence, dynactin functions as a processivity factor (Culver-
Hanlon et al., 2006) by helping dynein move a longer distance on the microtubule by 
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preventing its accidental diffusion into the cytoplasm. Recent studies show that mutations 
in dynactin inhibit the initiation of retrograde transport in neuronal axons (Lloyd et al., 
2012). This suggests that dynactin also functions as a cargo adaptor for dynein and 
initiates transport events at the plus ends of the microtubule. 
1.2 Role of the dynein-dynactin motor protein complex in cell maintenance 
Together the dynein-dynactin motor complex plays an essential role in the 
intracellular transport. Total loss of dynein function causes early embryonic lethality in 
Drosophila melanogaster (Dick et al., 1996). Dynein-null mouse embryos lacking dynein 
do not survive to the gastrulation stage (Harada et al., 1998). The dynein/dynactin motor 
protein complex transports cargo from the tip of the axon towards the neuronal cell body 
(retrograde direction). There have been several neurodegeneration disorders linked to 
mutations in dynein and dynactin genes (Levy and Holzbaur, 2006). This suggests that 
mammalian neurons are particularly sensitive to the dynein/dynactin mutations. A 
potential reason why neurons could be especially sensitive to the motor complex 
mutations will be discussed later. 
1.3 Dynein structure and function 
A dynein molecule (Fig.3) is about 1.2 mega Dalton in mass and is comprised of various 
subunits. The dynein subunits arranged in a motor complex are - 2 dynein heavy chains 
(DHCs), 2 dynein intermediate chains (DICs), 4 dynein light intermediate chains (DLICs) 
and 3 pairs of dynein light chains (DLCs). The tail region of DHCs interacts with the 
DLICs and together they interact with various other subunits (King et al., 2002). The 
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DICs have many interacting protein partners like dynactin, Bicaudal D (Bic D) 
(Hoogenraad et al., 2001), Lissencephaly (LIS 1) (Smith et al., 2000), Nuclear 
distribution protein E (NudE) (McKenney et al., 2010). Together these additional binding 
partners help dynein to be more adaptable to carry a variety of cargoes inside the cell. 
Overall, dynein carries out various important cellular processes like cargo trafficking 
(Traer et al., 2007), nuclear migration (Levy and Holzbaur, 2008), chromosome 
segregation during mitosis (Dujardin et al., 1998), cell division (Pfarr et al., 1990) and 
organelle positioning (Burkhardt et al., 1997). 
 
Figure 3: Dynein molecule structure 
A dynein molecule comprises of 2 dynein heavy chains, 2 intermediate chains (shown in light 
green), 4 light intermediate chains (shown in dark green) and 3 pairs of light chains (shown in 
yellow).  
The DHC subunits of dynein have the main role in the motor activity of the 
dynein. The DHCs participate in the transport process by hydrolyzing the ATP and 
generating force to take steps on the microtubule. Hence, the next subsection will explain 
the structure and the motor function of the DHCs, to better understand its importance in 
intracellular transport. 
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1.3.1 Dynein heavy chain 
The DHC is ~4500 amino acids long and is a member of the AAA+ domain 
protein family. The DHC can be divided into two regions – an N-terminus tail domain 
and a globular head domain (Fig.4 A). The N-terminal ends of two DHCs coil together 
and form a homodimer tail at the base of the dynein molecule. The tail domain regulates 
dynein and interacts with other dynein subunits and cargoes.  
The globular head domain has motor activity and contains 6 repeating units of 
AAA+ (ATPase Associated with various cellular Activities) ATPase sites arranged in a 
ring (AAA1-AAA6) (Burgess et al., 2004; Sakato and King, 2004). The AAA1 domain 
has a p-loop motif that binds and hydrolyzes ATP (Gibbons et al., 1991; Gibbons et al., 
1987; Koonce et al., 1992). Other domains, AAA2-AAA4 also have p-loop motifs and 
can bind ATP but appear incapable or less capable of hydrolyzing ATP. These secondary 
sites may serve as dynein function regulators (Mocz and Gibbons, 1996).  
 
Figure 4: Dynein Heavy Chains (DHCs) structure 
Left: The DHC has 2 regions- N terminus tail domain and a globular motor head. Right: The 
DHC crystal structure showing various globular motor domains with the microtubule binding 
domain (MTBD) crystal structure arising from it. (Adapted from Vale et al. 2012; Biochimica et 
Biophysica Acta) 
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The AAA5-AAA6 domains lack ATP binding and ATPase enzymatic activity (Neuwald 
et al., 1999), but act as structural supports to complete the ring structure of the dynein 
molecule. Dynein’s microtubule binding stalk is located between the AAA4 and AAA5 
domains(Koonce, 1997). 
Recently, DHC crystal structures have been published (Carter et al., 2011; Kon et 
al., 2011) and they show various structural features of the dynein molecule (Fig.4 B). 
These crystal structures give a better understanding of how the 6 AAA+ ATPase domains 
in the DHC globular head interact with each other. The DHC crystal structures also 
shows specific position of other dynein domains such as the linker, strut, and microtubule 
binding stalk and how they can help in nucleotide sensing and the motor function 
(Fig.4B).  
1.4 Dynactin structure and function 
Structurally, dynactin is ~ 1 mega Dalton molecule (Fig.5) and contains 11 
different subunits (Schroer, 2004). These dynactin subunits interact with dynein, 
microtubules and cargos. The largest dynactin subunit, p150, is ~1300 amino acid long 
and forms a dimer via a coiled coil region (CC-1). The CC-1 region interacts with the 
dynein intermediate chains (King et al., 2003) and overexpression of this domain has 
been used to uncouple dynein/dynactin function (Kwinter et al., 2009; Quintyne et al., 
1999). The overexpressed CC-1 domains bind strongly to dynein motors and outcompete 
the binding of dynactin to the dynein. Thus, in a CC-1 overexpressing cell, the vast 
majority of dynein cannot bind dynactin but instead are bound to CC-1. 
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Figure 5: Dynactin molecule structure 
The microtubule binding domain (MTBD) of dynactin contains the p150 subunit. Dynactin binds 
to the dynein through CC-1 domain. Other dynactin subunits (such as p25, p27, p50/dynamitin, 
p62, Arp1and Arp 11) interact and bind to the cargo. 
 
The p150 subunit has two microtubule binding domains (MTBD) at the N 
terminus. The first MTBD contains a conserved glycine rich CAP-Gly region (Fig.6, 
shown in green) and the second MTBD part contains a highly basic region (Fig.6, shown 
in blue). The CAP-Gly MTBD is needed for cargo attachment onto the microtubule and 
initiation of dynein/dynactin transport process (Moughamian and Holzbaur, 2012). The 
basic MTBD of p150 has a role in the processivity enhancement of the dynein/dynactin 
motor complex (Culver-Hanlon et al., 2006; Kincaid and King, 2006). 
 
Figure 6: The p150 subunit of dynactin 
Dynactin p150 contains 2 microtubule binding domain (MTBD): a glycine rich CAP-Gly region 
(shown in green) and a highly basic region (shown in blue). The MTBDs are followed by the two 
coiled coil regions CC-1 and CC-2 (shown in yellow) and some regions of unknown function 
(red). The CC-1 domain interacts with the dynein molecule.   
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The cargo binding domain of dynactin (Fig. 5) contains many subunits including 
p25, p27, p50/dynamitin, p62, Arp1 and Arp 11 that can bind to variety of different 
cellular cargoes (Schroer, 2004). For example, some dynactin subunits such as the 
filamentous actin related protein Arp1 interacts with the Golgi complex via spectrin 
linkages (Holleran et al., 2001) and the p50/dynamitin subunit interacts with the mitotic 
checkpoint proteins such as ZW10 (Starr et al., 1998). 
1.5 Role of the dynein-dynactin motor protein complex in neurodegeneration 
The dynein/dynactin motor complex has a role in the highly processive transport 
system required by neurons to carry essential molecules over long range distances. 
Consequently, mutations in the dynein/dynactin motor complex could potentially have a 
pronounced effect on neurons because of their long axonal morphology. For example, 
with normal velocity of 1μm/sec, the dynein/dynactin motor complex takes about 10 
seconds to transport cargo across a typical 10μm animal cell and takes more than 10 days 
to transport cargo in a 1 meter long neuron. In case there is a mutation in the 
dynein/dynactin complex that decreases its dynein velocity from 1μm/sec to 0.5μm/sec. 
Now, the mutant dynein/dynactin complex would take 20 seconds to deliver the same 
cargo across a 10μm animal cell, which may not cause an adverse effect. However, the 
same mutant dynein would take more than 20 days instead of 10 days to transport a cargo 
in a long neuron. This delay might cause a defect that leads to severe degradation of 
neuronal health. Hence, it seems apparent that there is a need for robust dynein/dynactin 
motor complex transport system inside neurons at all times to avoid defects in 
intracellular transport that may lead to neurodegeneration. In support of this concept, 
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there have been many neurodegeneration linked mutations identified in the 
dynein/dynactin motor protein complex as described in the following sections. 
1.5.1 Neurodegeneration linked mutations in dynein 
There are several human neurological disorders linked to mutations in the DHCs. 
A mutation was found in the DHC tail’s homodimerization domain where the histidine at 
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position gets replaced by an arginine residue (H306R). This H306R mutation in the 
DHCs was identified in the human patients suffering from the Charcot Marie Tooth 
(CMT) type 2O disease (Weedon et al., 2011). CMT type 2O is a motor neuron disease 
that causes impairment in the motor functions, gait abnormalities and arched feet (pes 
caveus) deformities in patients.  
Other neurodegeneration linked mutations - K671E, Y907C and I584L, in the tail 
region of the human DHC have been identified (Baloh et al., 2012). These mutations 
were identified in the human patients suffering from the Spinal Muscular Atrophy with 
Lower Extremity Predominance (SMA-LED). Some manifestations of the SMA-LED 
disorder in the patients included distal neuropathy, significant motor delay in infancy, 
muscular atrophy and proximal predominant leg weakness, waddling gait, awkward 
running and mild cognitive delay.  
In some patients other DHC mutations were identified – H3822P (Vissers et al., 
2010) and E1518K (Willemsen et al., 2012). These mutations caused neuronal migration 
defects, developmental delays, cortical malfunctions, severe speech impairment, 
intellectual inability and mental retardation, waddling gait and reduced tendon reflexes. 
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Three other DHC mutations have been identified in mice, which are a common 
model system to study neurodegeneration (Chen et al., 2007; Duchen, 1974; Hafezparast 
et al., 2003). These mutant mice are Cramping (Cra 1), Legs at odd angles (Loa) and 
Sprawling (swl) and they developed neurodegenerative defects. These neurodegenerative 
mutant mice displayed flaws in their posture and motor coordination. When these mice 
were subjected to the tail suspension test, they displayed abnormal clasping and 
clenching of their hind limbs and toes (Banks and Fisher, 2008). With time these 
heterozygous mutant mice developed late onset of motor neuron disorders. Further 
characterizations of Cra1 and Loa mice neurons revealed impaired motility associated 
with reduced dynein processivity (Hafezparast et al., 2003; Ori-McKenney et al., 2010). 
To conclude, mutations in the DHC region have been reported to cause 
neurodegenerative phenotypes in humans and in mice. A very interesting point is that all 
of the known mutations in the DHC have been linked to neurodegenerative disorders. 
There are no other DHC mutations that cause other types of diseases, suggesting that 
neurons are the most sensitive to the defects in dynein function. Another point to note is 
that no neurodegeneration linked mutations have been reported in other components of 
dynein (DICs, DLCs and DLICs). 
1.5.2 Neurodegeneration linked mutations in dynactin 
There are several disease linked mutations in the p150 subunit of dynactin (Fig.7) 
that are linked to human neurodegenerative diseases. For example, the G59S mutation in 
the CAP-Gly region of the p150 subunit of dynactin has been linked to distal Spinal 
Bulbar Muscular Atrophy (dSBMA) (Chevalier-Larsen et al., 2008). The patients 
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suffering from dSBMA have an onset of progressive motor neuron disorder, paralysis in 
the vocal cords and/or weaknesses in face, hand and lower extremities (Puls et al., 2003). 
Mutant mouse models having G59S mutations showed motility defects and developed 
disease conditions related to motor neuron disorders (Lai et al., 2007). Another set of 
mutations (G71E, G71A, G71R, T72P and Q74P) in the same CAP-Gly region leads to 
Perry syndrome (Farrer et al., 2009). Perry syndrome characteristics involve 
Parkinsonism, hypoventilation, weight loss and depression in humans in their late 40s or 
50s. Other mutations (M571T, R785W, R1101K and T1249I) near the CC-1 and CC-2 
domain of dynactin have been linked to Amyotrophic lateral sclerosis (ALS) (LaMonte et 
al., 2002), but no further work has been reported on these mutations. 
 
Figure 7: Neurodegenerative linked mutations in dynactin 
Localization of neurodegenerative disorders (dSBMA, Perry syndrome and ALS) linked 
mutations in dynactin. 
1.6 Hypothesis: Dynein/dynactin motor protein complex and Neurodegeneration 
It is very intriguing that all of the known mutations in dynein and dynactin cause 
neurodegenerative disorders and no other types of diseases. As discussed previously, the 
morphology of long axons might make neurons more sensitive than other cell types to 
potential transport defects caused by mutations in the dynein/dynactin motor protein 
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complex. In contrast, severe dynein mutations (DHCΔ) result in the death of complex 
organisms (Harada et al., 1998). However, some mutations in the dynein/dynactin motor 
complex can moderately alter the intracellular transport in neurons and instead cause 
neurodegenerative phenotypes.  
Based on the abovementioned line of conjecture, the King lab has developed a 
hypothesis: Neurodegenerative phenotypes of mutations in the dynein/dynactin motor 
protein complex are due to subtle, and not severe, defects in intracellular transport. 
To test this hypothesis, our aim is to study the effects of dynein/dynactin motor 
complex mutations on the long neuronal transport. But due to the inherent difficulties of 
working with neuronal cultures, my own approach was to use simpler cell systems to set 
a ground work to initially test the effects of dynein and dynactin disruptions on 
intracellular transport. In the approach detailed in Chapter 2, the effects of several 
spontaneous DHC mutations on transport were characterized in the fungi Neurospora 
crassa. In another set of experiments detailed in Chapter 3, the dynein/dynactin complex 
was disrupted in the mammalian CAD cell line and consequent effects on mitochondrial 
motility were studied. In support of our hypothesis, in each experiment I was able to 
determine that a moderate loss of dynein/dynactin function correlated with subtle 
transport defects whereas severe loss of dynein/dynactin function resulted in more severe 
phenotypes that would likely cause cells to die.  
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CHAPTER 2: N. crassa MOTILITY ANALYSES 
2.1 Introduction: N.crassa as a model system to study dynein function 
In most eukaryotes, dynein is an essential protein for cell survival and is needed 
to carry out many necessary functions during embryonic development. Total loss/deletion 
of dynein causes early embryonic lethality in homozygous DHCΔ animals (Hafezparast 
et al., 2003; Harada et al., 1998). Hence, there is a challenge to carry out dynein 
alterations and mutational analyses in many eukaryotic systems. However, dynein is not 
essential for N. crassa survival and the gene can be mutated or altered in a variety of 
genetic ways. Moreover, the N. crassa has a haploid genome, which has the advantages 
that 1) all effects/phenotype of the mutation will be observed since there are no 
recessive/dominant allele expression, 2) all proteins present have same genetic basis so 
all dynein would be equal and 3) the uniformity of genetic alteration can be established in 
the pool of all the dynein motors. 
Hence for one aspect of my Thesis project, I studied and characterized the 
motility parameters of various spontaneous DHC mutations developed in N. crassa. I 
characterized the vesicular transport in Wildtype (WT) and DHC mutant strains using 
live cell imaging followed by kymograph analyses. 
2.2 Background work on N. crassa 
2.2.1 The ropy mutants 
A collaboration between the King and Plamann Lab (University of Missouri, 
Kansas City) made use of a genetic trick with the colonial temperature sensitive (cot-1
ts
) 
mutant strain to study dynein function in N. crassa (Plamann et al., 1994). The cot-1
ts
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mutant strain of N. crassa grows like the wildtype strain at the permissive temperature 
(28°C) with normal radial colony morphology. When the temperature is raised to 37°C, 
the cot-1
ts
 mutant strain shows a constrained growth (Fig 8). At a low frequency some N. 
crassa colonies undergo spontaneous mutations in genes that suppress the temperature 
sensitivity of the cot-1
ts
 strain at 37°C. These suppressed colonies are able to grow at the 
restrictive temperatures (37ºC). When these suppressed colonies are isolated and grown 
back at the 28°C permissive temperature, they grow as ropy mutant colonies having 
highly branched hyphae.  
 
Figure 8: The ropy mutant colony morphology 
The cot-1
ts 
is a temperature sensitive strain of N. crassa (top left panel) and has a suppressed 
growth at the restrictive temperature of 37°C (top right panel). Revertant
 
colonies pick up 
mutations to suppress the cot-1
ts
 mutation and grow at 37°C (bottom left panel). When grown 
back at 28°C, these cot-1
ts
 suppressant colonies have highly branched hyphae with ropy 
phenotype (bottom right panel). (Adapted from Sivagurunathan et al., 2012; Genetics) 
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2.2.2 Isolation of N. crassa DHC class mutants 
For a collaborative project between the King Lab and the Plamann Lab, several 
hundred of these cot-1
ts
 suppressant ropy colonies were isolated and characterized 
(Sivagurunathan et al., 2012b). Several sequential identification steps (Fig. 9) were 
applied on the isolated ropy mutant colonies.  
 
 
 
 
 
 
 
 
Figure 9: Isolation of N. crassa DHC class mutants 
The flowchart shows the steps followed to isolate, identify and classify various N. crassa ropy 
mutant strains. The text next to the arrows indicates the procedural action followed to achieve the 
next mentioned step. 
 
Out of 690 mutant colonies, 290 ropy mutant colonies were isolated that had 
mutations only in the DHC gene. The remaining 400 mutant colonies had defects in other 
components of dynein and dynactin and were not analyzed further. Western blot was 
performed on the 290 DHC mutant colonies to identify which of those colonies produced 
full length DHC. 76 mutant colonies were isolated that produced full length DHC and 
those mutations were sent for DNA sequencing. From DNA sequencing it was identified 
that 44 colonies had a frameshift or nonsense mutation in the DHC and were discarded, 
Isolated 690 ropy colonies 
Found 290 colonies containing mutations in the DHC  
Isolated 76 mutant colonies producing full length DHC 
Identified 34 colonies with single genetic lesion for further 
analyses 
Classied into 5 different classes based on the mutant phenotypes 
Backcrossed with WT 
Western blot 
DNA sequencing 
Fluorescence microscopy 
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except for 2 frameshift mutants that produced slightly shortened DHC. These 2 mutants 
were considered for analysis along with 32 other mutant strains that had only single point 
mutations in the DHC region.  
Next, these 34 ropy mutant strains were crossed with a N. crassa strain having 
mCherry tagged DIC and GFP labeled tubulin. This step was performed to identify the 
localization of dynein and the microtubules in ropy mutants. Based on the 
immunofluorescence microscopy and biochemical assays, these 34 ropy mutants were 
then classified into 5 different classes of DHC mutant phenotypes (Fig.10) 
(Sivagurunathan et al., 2012b). 
 
 
                    Figure 10: Comparison of DHC class mutant phenotypes 
The images show different phenotypes of DHC class mutants as compared to the Wildtype (WT) 
phenotype. The first column shows the dynein localization (red channel) and the second column 
shows the microtubule localization (green channel) in hyphae. The third column shows a merged 
image of the red and the green channel. Scale bar = 10µm. (Adapted from Sivagurunathan et al., 
2012; Genetics) 
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In the wildtype (WT) N. crassa hyphae, the dynein was localized as a bright pool 
in the hyphal tip (Fig.10) and was dimmer at other locations in the hyphae. However for 
the 5 different DHC mutant classes, the dynein localization at the bright hyphal tip was 
abolished. In DHC mutant strains, the dynein got localized to the other locations such as 
away (distal) from the hyphal tip (Class 1), near (apical) the tip (Class 2), on the MT ends 
as comets (Class 3), clustered in aggregates (Class 4) and diffused along the hyphae 
(Class 5). The microtubules in the DHC class mutant strain were also disorganized in 
comparison to the microtubules in the WT hyphae. Also, the hyphal tips of the DHC class 
mutants grew at a slower rate as compared to the WT strain. 
It was found that these 34 DHC mutations spanned all through the 6 AAA+ 
ATPase domains and the tail region (Fig.11A). Also, these mutations could be mapped on 
a DHC crystal structure (Fig.11B) to correlate between the position of these mutations in 
the DHC and the resultant mutant phenotype. Interesting things can be learned from the 
mutations mapping on crystal structure. For example, it seems that the Class 5 mutations 
highlighted in orange are all over the DHC polypeptide (Fig. 11A), but from the crystal 
structure it can be seen that Class 5 mutations are localized close to each other (Fig. 11B). 
Similarly, Class 1 mutations (highlighted in blue) that are localized in different domains 
on the DHC polypeptide can be seen localized near each other on the DHC crystal 
structure. Hence, it is useful to have the DHC polypeptide mutations be mapped onto a 
crystal structure as it gives a better visualization of how the mutations localize on a three 
dimensional globular DHC structure may share common mechanisms of action. 
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Figure 11: Localization of DHC class mutations 
The DHC class mutations were mapped on the DHC polypeptide (A) and on the DHC crystal structure (B). The 34 DHC mutations span 
across all ATPase domains as well as the tail region of the DHC polypeptide. (Adapted from Sivagurunathan et al., 2012; Genetics) 
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2.2.3 Generation of N. crassa Loa mutants 
The collaborating labs were also interested to see what phenotypes N. crassa 
would develop with neurodegenerative mouse mutant dynein alleles. Hence, they decided 
to make a N. crassa Loa mutant strain.   
A Loa mutant mouse with a missense mutation F580Y in the DHC tail region 
develops neurodegeneration. This F580Y mutant heterozygous mouse had abnormal 
posture, defects in neuronal migration, muscle weakness and late onset of motor neuron 
disorder (Banks and Fisher, 2008). During a tail suspension test (Fig.12), the mutant 
mouse clasped its hind limbs together and displayed an abnormal phenotype of legs at 
odd angle and acquired its name as Loa (Legs at odd angle) mouse.  
 
Figure 12: Tail suspension test 
Left: A wildtype mouse displaying normal splayed hind limb phenotype during the tail 
suspension test. Right: A mutant Loa heterozygous mouse displaying abnormal “Legs at odd 
angle” phenotype during the tail suspension test. (Adapted from Fisher et.al 2008, Genome 
Biology) 
 
The neurons extracted from the heterozygous Loa/+ mouse showed a slight defect 
in the retrograde axonal transport of lysosomes (Ori-McKenney et al., 2010). The 
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homozygous Loa/Loa mouse was embryonic lethal and the neurons extracted from it 
showed a significant defect in the retrograde axonal transport (Hafezparast et al., 2003). 
The same Loa mutation was studied and characterized in N. crassa 
(Sivagurunathan et al., 2012a). Due to the structural conservation of DHC (Fig.13) 
between N. crassa and the higher eukaryotes, it was possible to generate the 
corresponding Loa mutation (F607Y) in the N. crassa DHC tail region.  
 
Figure 13: Loa tail mutation in N. crassa DHC 
Structural conservation of DHC exists between N. crassa and the higher eukaryotes. This makes 
it possible to generate mouse neurodegenerative Loa mutation in N. crassa. The Loa mutation is a 
F607Y missense mutation in the DHC tail region. . (Adapted from Sivagurunathan et al., 2012; 
Cytoskeleton) 
 
The hyphal morphology of mutant Loa N. crassa (Fig.14) was intermediate 
between that of WT and ropy DHC class mutants. Also, the dynein pool at the hyphal tip 
of the Loa mutant strain was reduced as compared to the WT hyphae, but it was not 
completely abolished like what was observed for the 5 DHC ropy class mutants (Fig.10). 
Now, the next question was if the DHC class mutations and the Loa mutation cause any 
defects in the vesicular transport of N. crassa.  
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Figure 14: Localization of dynein in the mutant Loa N. crassa strain 
First column shows the dynein localization (red channel) and the second column shows the 
microtubule localization (green channel) in the N. crassa hyphae. The third column is a merged 
image of the red and green channel. Compared to the wildtype strain, the dynein localization is 
reduced at the hyphal tip in the Loa mutant. Scale bar = 10µm. (Adapted from Sivagurunathan et 
al., 2012; Cytoskeleton) 
 
 
2.3 Results and discussion 
2.3.1 N. crassa DHC class mutants results 
Mutations in the DHC affected dynein localization in N. crassa hyphae. The 
transport of FM 4-64 labeled vesicles in the growing hyphal tip of WT and DHC mutants 
were recorded using live cell imaging and the motility analysis was performed using 
kymographs. 
2.3.1.1 Kymograph and motility analyses 
Kymographs were plotted and analyzed to study the motility patterns of the FM 4-
64 labeled vesicles in N. crassa hyphae.  
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Figure 15: Kymographs of the FM® 4-64 labeled vesicles in N. crassa hyphae  
Kymographs (i.e. distance vs. time graphs) for various N. crassa controls – Wildtype (WT), 
DHCΔ and p150Δ. On a kymograph, the diagonal line (white arrow) represents a moving vesicle 
and the vertical line (black arrow) represents a stationary vesicle. Less number of diagonal lines is 
present in the DHCΔ and p150Δ mutant strains indicating lesser motility events than the WT. 
(Adapted from Sivagurunathan et al., 2012; Genetics) 
 
 
In WT kymograph (Fig.15), there were numerous diagonal lines representing high 
amount of vesicular motility inside the WT hyphae. But for the control mutant strains 
(DHCΔ, p150Δ and Nkin) and the DHC class mutant strains (Classes 1-5), less number of 
diagonal lines were present on the respective kymographs (Fig. 15 & 16). This signifies 
that there was a decrease in the number of motility events inside the N. crassa mutant 
hyphae.  
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Figure 16: Kymographs of N. crassa mutant strains 
Kymographs (i.e. distance vs. time graphs) for various N. crassa mutant strains show less number 
of diagonal lines indicating lesser motility events than the WT. (Adapted from Sivagurunathan et 
al., 2012; Genetics) 
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Data on various motility parameters such as run lengths, velocities and the 
number of movements were generated for FM 4-64 labeled vesicles based on the N. 
crassa (WT and mutant) kymographs.   
Compared to the N. crassa WT strain, the DHC class mutant strains showed a 
decrease in various motility parameters (Table 1). Overall, there was about 50-80% 
reduction in the motility index for the DHC mutant strains as compared to the WT. Also, 
I observed a decrease in the mean movements of vesicles happening over a micron length 
of mutant hyphae strains. Correspondingly, less number of vesicular movements (N) was 
recorded for the mutant strains than for the WT. 
 For all the DHC class mutants and controls (Table 1), I determined that there was 
a significant decrease in the mean velocity of the vesicular movements.  In addition to 
that, a significant decrease was also seen in the mean distances travelled by the vesicles 
in most of the mutant strains, except for Class 1 and Class 5. Hence, it can be concluded 
that most of the DHC mutations affected the overall intracellular transport, as seen by the 
decrease in the mean velocity and distance. To get an assessment of overall motility 
measures, an index was generated by combining all the motility parameters. That is, the 
motility index was calculated by adding all the distances multiplied with respective 
velocities for all the motility events and that value was divided by the total hyphal length 
analyzed.  
Motility index= ∑ (Distance x Velocity) 
           hyphal length analyzed 
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Table 1: Comparison of motility parameters for the N.crassa WT and mutant strains 
  Wildtype DHC Δ p150 Δ Nkin 
mut. 
Class 1 Class 2 Class 3 Class 4 Class 5 
Motility index 21.5 5.8 8.3 4.1 10.4 4.9 9.4 7.4 6.2 
Overall movements 
Mean movements/ 
µm hyphal length 
2.9 1.2 1.8 0.8 1.5 1.2 2.4 1.7 1.1 
N 557 185 286 162 199 110 247 200 170 
Mean velocity 
 (µm/sec  S.D.) 
1.64  
0.59 
1.46  
0.62* 
1.34  
0.49* 
1.35  
0.52* 
1.51  
0.59* 
1.24  
0.41* 
1.33  
0.45* 
1.33  
0.41* 
1.31  
0.48* 
Mean distance 
(µm  S.D.) 
4.26  
0.54 
3.03  
1.71* 
3.19  
1.44* 
3.49  
2.07* 
4.48  
2.59 
3.21  
1.64* 
2.85  
1.15* 
3.17  
1.33* 
3.96  
2.33 
Various motility parameters are listed out for the Wildtype (WT), controls and the DHC class mutant strains. The table shows the overall 
motility events of the vesicles travelling in all the directions inside the hyphae. The ‘*’ indicates statistically significant difference from the 
WT value as determined by the Student’s T-test (P < 0.05). . (Adapted from Sivagurunathan et al., 2012; Genetics) 
 
Table 2: Vesicle accumulation in N. crassa hyphae 
  Wildtype DHC Δ p150 Δ Nkin 
mut. 
Class 1 Class 2 Class 3 Class 4 Class 5 
Vesicle accumulation 
Hyphal tip vesicle 
accumulation 
60.0 % 92.3 % 27.3 % 100 % 72.7 % 86.7 % 90.0 % 78.6 % 100 % 
Hyphal body 
vesicle 
accumulation 
13.3 % 7.7 % 90.9 % 0 % 9.1 % 6.7 % 20.0 % 21.4 %  0 % 
  
The percentage (%) represents the number of movies that display the mentioned vesicle accumulation phenotype out of the total number of 
movies. The p150Δ strain has the altered ratio of vesicle accumulation and is highlighted in red to indicate the difference with respect to the 
WT. (Adapted from Sivagurunathan et al., 2012; Genetics)  
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Table 3: Comparison of motility parameters for the inward and the outward directed vesicular movements 
  Wildtype DHC Δ p150 Δ Nkin 
mut. 
Class 1 Class 2 Class 3 Class 4 Class 5 
Inward movements 
Percent of total 
movements 
48.7 % 47.1 % 48.9 % 48.8 % 41.7 % 52.7 % 53.8 % 41.5 % 47.1 % 
Mean velocity 
 (µm/sec  S.D.) 
1.60  
0.55 
1.36  
0.53* 
1.27  
0.51* 
1.36  
0.53* 
1.43  
0.54* 
1.23  
0.45* 
1.29  
0.48* 
1.24  
0.40* 
1.28  
0.53* 
Mean distance 
(µm  S.D.) 
4.16  
2.47 
2.70  
1.27* 
2.78  
1.12* 
3.23  
1.88* 
3.90  
2.62 
2.86  
1.38* 
2.69  
1.02* 
2.66  
0.96* 
3.77  
2.40 
Outward movements 
Percent of total 
movements 
51.3 % 52.9 % 51.1 % 51.2 % 58.3 % 47.3 % 46.2 % 58.5 % 52.9 % 
Mean velocity 
 (µm/sec  S.D.) 
1.67  
0.61 
1.55  
0.69 
1.41  
0.47* 
1.35  
0.51* 
1.56  
0.62 
1.24  
0.36* 
1.38  
0.42* 
1.40  
0.41* 
1.35  
0.44* 
Mean distance 
(µm  S.D.) 
4.36  
2.60 
3.32  
1.98* 
3.59  
1.59* 
3.75  
2.22* 
4.89  
2.49 
3.57  
1.83* 
3.05  
1.27* 
3.53  
1.45* 
4.13  
2.26 
* = statistically significant difference from wild-type value as determined by students t-test (P < 0.05). 
Various motility parameters are listed out for the Wildtype (WT), controls and the DHC class mutant strains. The table shows the overall 
motility events of the vesicles travelling in the inwards and the outward directions inside the hyphae. The ‘*’ indicates statistically significant 
difference from the WT value as determined by the Student’s T-test (P < 0.05). (Adapted from Sivagurunathan et al., 2012; Genetics) 
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N.crassa movies for the WT and the mutant strains were also analyzed for the 
localization of FM 4-64 labeled vesicles inside the hyphae. For the WT and the mutant 
strains, it was observed that the vesicles accumulated more predominantly at the hyphal 
tip than in the hyphal body (Table 2). However, this vesicular accumulation pattern 
appeared to be altered in the p150Δ mutant strain and the reason is uncertain. 
The overall motility analysis was separated based on the direction of the FM 4-64 
labeled vesicles movements in the hyphae (Table 3). The vesicles that moved towards the 
hyphal tip were considered as the outward directed movements. And the vesicles that 
moved in towards the hyphal body were considered as the inward directed movements. 
Overall, I found no significant difference between the percentage of vesicles moving in 
the inward or outward direction for the WT and the DHC mutant. I observed that all the 
DHC mutant strains showed a significant decrease in the inward mean velocity, whereas 
for outward movements only some of the DHC mutant strains showed a decrease in the 
mean velocity. For the mean distances, I saw a significant decrease in the inward as well 
as outward directed movements in all the DHC mutant strains, except for Class 1 and 
Class 5. 
From this work it is apparent that 1) DHC class mutations caused a severe and 
similar kind of transport defect that resulted in a significant decrease of various motility 
parameters; 2) the overall pattern of the transport defects observed in the DHC class 
mutants were comparable to that of DHCΔ mutant strain transport defects; and 3) if the 
N. crassa DHC class mutations would be generated in the mice, then these class 
mutations would cause severe transport defects and can lead to embryonic lethality 
similar to the DHCΔ mutation.  
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2.3.2 N.crassa Loa mutant results 
The mouse neurodegenerative Loa mutation was generated in the N. crassa DHC 
to study the effect of this mutation on vesicular transport. The transport of FM 4-64 
labeled vesicles in the growing hyphal tip of WT and Loa mutants were recorded using 
live cell imaging and the motility analysis was performed using kymographs. 
2.3.2.1 Kymograph and motility analyses 
Kymographs were plotted and analyzed to study the motility patterns of the FM 4-
64 labeled vesicles in the WT and the mutant Loa hyphae.  
 
 
 
 
 
 
  
 
 
 
 
 
Figure 17: Kymographs of the vesicles in the WT and mutant Loa hyphae 
Kymographs (i.e. distance vs. time graphs) for various Wildtype (WT) and Loa mutant hyphae 
were generated. On a kymograph, the diagonal line (white arrow) represents a moving vesicle and 
the vertical line (black arrow) represents a stationary vesicle. (Adapted from Sivagurunathan et 
al., 2012; Cytoskeleton) 
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It can be seen from the kymographs that there were comparable number of 
diagonal lines in the WT as well as in the mutant Loa hyphae (Fig.17). This signifies that 
the WT and Loa hyphae have similar motility patterns. Data on run lengths, velocities 
and number of movements was generated for FM 4-64 labeled vesicles based on the N. 
crassa hyphae (WT and Loa) kymographs and is summarized in Table 4. 
 
Table 4: Summary of motility analysis of WT and Loa strains 
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The motility index for the WT and the Loa mutant strain was similar to each other 
(Table 4) and it correlated with the comparable number of motility events as observed on 
their kymographs. The mean number of movements per micron hyphal length and the 
number of movements (N) did not show any reduction in the Loa mutant strain. 
Both, the WT and the Loa mutant strain showed that the percentage of the inward 
directed vesicles was more than the outward directed vesicles (Table 4). In Loa mutant 
hyphae, I did not see any significant change in the mean distance (µm) of the inward or 
outward directed vesicles. However, I determined and statistically verified that there was 
a slight yet reproducible decrease in the mean velocity (µm/s) of inward directed vesicles 
in the Loa mutant hyphae as compared to the WT.  
Lastly, it can be concluded that the Loa mutation did not cause a severe reduction 
in the motility parameters as previously seen in the 5 DHC class mutations of N. crassa. 
Nevertheless, the corresponding Loa mutation causes neurodegeneration in the Loa 
mutant mice. This implies that a mutation which results in a subtle transport defect is 
adequate enough to cause neurodegeneration. Furthermore, likelihood can be based on 
the observed N. crassa data and that is, a rigorous mutation like DHCΔ or any of the 
comparable 5 DHC class mutants would cause severe transport defects. It can be a 
possibility that severe transport defects might lead to death instead of causing 
neurodegeneration in the corresponding mutant organism. 
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2.4 Future directions 
The Loa mutation did not cause a severe reduction in the motility parameters as 
previously seen in the 5 DHC class mutations of N. crassa. Hence, it can be determined 
that diverse N. crassa mutations (DHC class mutants and the Loa mutant) altered the 
intracellular motility but in different fashions. This indicates that these mutations do not 
utilize the same mechanism of action to affect dynein function.  
In the future, it will be useful to study and understand the mechanism of how can 
these 5 DHC class mutations of N. crassa affect the dynein function as well as the 
intracellular transport in mice. For this purpose, one of the 5 DHC class mutations of N. 
crassa can be generated into a mice model. However, because these DHC class mutations 
are comparable to the DHCΔ mutation, it is most likely these DHC class mutations might 
cause embryonic lethality in the respective mutant mice model similarly to the DHCΔ 
mutant mouse model. Given the time and effort required to create a mutant mouse model, 
it would not seem worthwhile to create a mouse model which might be embryonic lethal. 
Other future approaches can include generating DHC linked human 
neurodegenerative mutations in N. crassa. With all the given advantages of this fungi 
model system, it will be productive to study the effects of these neurodegenerative 
mutations on intracellular transport. If these mutant strains show subtle transport defects, 
then in support of it, our hypothesis can provide a possible mechanism of action of these 
neurodegenerative mutations. 
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CHAPTER 3: CAD CELLS MOTILITY ANALYSES 
3.1 Introduction 
Our long term goal is to study dynein and dynactin mutations in neurons. As a 
step in that direction, I utilized the mouse CAD cells for studying mitochondrial transport 
after impairing the dynein/dynactin motor complex. 
3.2 Rationale for the approach 
The CAD cell line is a mouse tissue culture cell system in which the cells were 
derived from a mouse brain tumor (Suri et al., 1993). These cells have synaptic vesicles 
and proteins similar to that found in neurons. When CAD cells are grown in a serum free 
medium, these cells extend out long projections that have resemblances to those in 
neurons (Fig.18) (Qi et al., 1997). Therefore, the CAD cell line can serve as an easy to 
use mammalian cell system to study long range transport. 
 
Figure 18: CAD cell in culture 
CAD cells extend projections like neurons when grown in a serum free media. Scale bar = 5µm. 
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A recent study has shown that human neuropathy linked to DHC mutations may 
cause progressive mitochondrial dysfunction (Eschbach et al., 2013). Therefore, I decided 
to utilize mitochondria as a cargo to study the effects of dynein/dynactin motor protein 
complex impairments on intracellular transport in CAD cells. The mitochondria were 
visualized with an easy to use MitoTracker Green dye to track their motility during live 
cell imaging. 
Two different approaches were applied to impair the dynein/dynactin motor 
complex: 1) Disrupting dynactin function with shRNA based approach and 2) inhibiting 
dynein function using a newly available drug Ciliobrevin (Firestone et al., 2012). 
As descried in Chapter 1, the p150 subunit of dynactin binds and interacts with 
microtubules. shRNA technology was utilized to knock down the p150 subunit of 
dynactin in CAD cells. For a long term project goal, we wanted to study the effects on 
intracellular transport under the loss of function or reduction of dynactin levels (as caused 
by knockdown) and under the presence of neurodegeneration linked mutant dynactin 
(expressed exogenously) in CAD cells. Hence, we followed a “knockdown and 
replacement” strategy to support our future project goal (Fig.19). This two-step strategy 
was followed to avoid secondary effects of dynactin cable structure formation that are 
caused due to high amounts of dynactin inside the cell. Therefore, to maintain the normal 
level of dynactin inside the cell, endogenous p150 levels have to be reduced by 
knockdown and then replaced by the expression of exogenous mutant dynactin. 
Subsequent effect of exogenous expression of mutant dynactin on intracellular motility 
would be characterized to understand its mechanism of action.  
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Figure 19: p150 subunit ‘knockdown and replacement’ strategy in CAD cells 
Due to the p150 knockdown effect (A), the endogenous level of dynactin reduces in the cell (B). 
During the replacement step (C), a new p150 construct is expressed to generate new exogenous 
dynactin in the cell. (Blue p150 = endogenous dynactin. Red p150 = exogenous dynactin) 
 
Alternate methods of disrupting dynactin function include overexpressing the  
CC-1 domain or the p50/dynamitin subunit of dynactin (Fig.20). Overexpression of the 
CC-1 domain causes that polypeptide to out-compete endogenous dynactin and bind to 
the dynein motor instead (King et al., 2003; Kwinter et al., 2009; Quintyne et al., 1999).  
 
Figure 20: Other methods of disrupting dynactin function 
Overexpression of the CC-1 domain or the p50/dynamitin subunits disrupts dynactin function 
inside the cells.  
 
Overexpression of the p50/dynamitin subunit fragments the dynactin complex and 
disrupts its function (Echeverri et al., 1996; Eckley et al., 1999; Karki et al., 1998). These 
overexpression methods to disrupt dynactin function were not employed because they 
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would interfere with the abovementioned future goal of exogenously expressing 
neurodegeneration linked mutant dynactin and studying its effect. 
The compound Ciliobrevin is a small molecular inhibitor of dynein. Ciliobrevin 
blocks the enzymatic activity of the AAA+ ATPase domains of dynein (Fig. 21). In this 
way Ciliobrevin is thought to inhibit the dynein motor in vitro and in vivo (Firestone et 
al., 2012). Hence, because of its specificity in action and ease of use, the Ciliobrevin drug 
was used to inhibit dynein function in my experiments. 
Figure 21: Ciliobrevin inhibits dynein’s motor activity 
Ciliobrevin is thought to block the enzymatic activity of the ATPase domains of the dynein 
motor. This result in the inhibition of dynein motor activity and dynein cannot move along a 
microtubule. 
3.3 Background work: p150 knockdown quantification 
For my motility experiments, it was critical to determine the extent of p150 
knockdown from the shRNA approach. Unfortunately, we only had low percentage of 
transfected cells, so western blot analyses were not conclusive for determining p150 
levels in transfected cells. However, the knockdown plasmid had another sequence 
encoding the red mCherry fluorescent protein to report which cells were transfected. 
Therefore, the King lab utilized immunofluorescence based approach to quantify the 
p150 knockdown in CAD cells. 
Ciliobrevin 
 37 
 
For immunofluorescence staining experiment, the transfected CAD cells were 
fixed on a coverslip and immunostained with a primary antibody against the p150 subunit 
of dynactin and Alexa Fluor® 488 secondary antibody (Molecular Probes®) which 
fluoresced green. Images of view fields of cells containing both transfected (red signal) 
and untransfected (non red) cells were captured using our EMCCD camera. The 
fluorescence intensities of each cell were determined in both the red and green channels. 
The red channel gave the intensities of mCherry transfected cell and green channel gave 
the intensities of p150 indicating its level inside the cells. 
 From initial qualitative image assessment (Fig. 22), we could see that those cells 
which had sh p150 red fluorescent signal also had diminished green fluorescence signal. 
This implies that the red transfected cells on the sh p150 coverslip showed reduced 
amount of dynactin level due to knockdown. This was not observed for the control sh 
SCR transfected red cells. p150 levels in the sh SCR control cells were clearly not 
abolished although there was a clear reduction perceived by the eyes. We also noted that 
the Golgi apparatus maintained a tight phenotype in both control and p150 knockdown 
cells, indicating that we had not reduced the amount of dynactin to the point where Golgi 
fragmentation occurs (Holleran et al., 1998). 
This qualitative screening was carried out for various time points i.e. 48h, 72h and 
96h post transfection to check the maximum knockdown efficiency of sh p150 plasmid. It 
was determined that the best knockdown was achieved at 72h post transfection time 
point. Hence, later motility experiments were carried out in the cells at the 72h post 
transfection time point.  
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Figure 22: Immunostaining displaying p150 knockdown at 72 hrs 
1
st
 column-mCherry signal indicates transfected CAD cells; 2
nd
 column- green p150 signal indicates level of p150 subunit; 3
rd
 column- Giantin 
signal shows Golgi phenotype; 4
th
 column- shows a merged image of all 3 channels. The sh p150 transfected red cells show a dimmer green 
intensity than untransfected and sh SCR red cells. (Data provided by Ranit Ghosh) 
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To quantitatively determine the knockdown efficiency, we determined the red and 
green fluorescence signals for each individual cell (Fig. 22). Then the data for each cell 
was plotted so that comparison can be made (Fig. 23). Each data point represented a 
single cell on the graph. The control cells (green data points) were untransfected ‘no 
DNA’ cells and these cells showed high levels of dynactin above 12,000 arbitrary units 
(au) on the y-axis. The sh SCR transfected cells (red data points) had high levels of 
dynactin above 10,000 au, independent of their mCherry red intensities (x-axis).  
The sh p150 cells (blue data points) had two populations of transfected cells. First 
population contained those cells with red fluorescence below 10,000 au and these cells 
were either non-transfected (non red) or likely to be weakly transfected with no 
significant decrease in the p150 levels on y-axis. As seen from the inset image in Fig. 23, 
the control cell green data points basically show the background auto fluorescence of the 
cell at 1000 au red levels and in these cells level of p150 intensity was high. Similarly, 
the sh SCR and sh p150 cells with background auto fluorescence were at low red levels 
and showed high levels of p150 intensities. 
The second population of sh p150 cells were noticeably transfected above the 
10,000 au of red intensities. These truly transfected cells had reduced p150 levels as 
compared to the control and sh SCR cells, showing the knockdown effect of the sh p150 
plasmid. Based on these results, a threshold line (shown in yellow) to determine the 
transfection was drawn at 10,000 au levels on x- axis. Hence, I performed my motility 
analyses only on cells with red intensities above 10,000 au, to ensure that these cells were 
truly transfected and the p150 knockdown effect has occurred in these cells.  
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Figure 23: Quantification of p150 knockdown at 72 hrs 
A graph was plotted between the red intensity of the transfected cells (x-axis) vs. green 
fluorescence intensity of dynactin level (y-axis). Each data point represents a single cell. The 
yellow line drawn at 10,000 au indicates a separation threshold point between the two populations 
of cells as described in the text. (Data provided by Ranit Ghosh). 
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3.4 Results and discussion 
3.4.1 Effects of dynactin disruption on motility 
To study the effects of dynactin disruption on the mitochondrial motility, live cell 
imaging for motility events were recorded from different portions on coverslip and the 
imaging experiments was repeated on three different days. From the collected data of live 
cell movies, I picked up cells that had red fluorescent intensities more than 10,000 au for 
truly sh p150 and sh SCR transfected cell. In these movies, I observed that more number 
of mitochondria were actively transported in the WT and sh SCR control cells than in the 
sh p150 knockdown cells.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Kymographs of mitochondrial movements in CAD cells 
The control Wildtype (WT) and sh SCR kymographs show more diagonal lines than the sh p150 
knockdown kymograph. Because each diagonal line represents a motility event, therefore there 
was less motility events observed in sh p150 knockdown cells. (Distance on x-axis and time on y-
axis) 
   
Distance 
T
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From respective live cell movies, kymographs (Fig. 24) were generated for the 
WT, sh SCR control and sh p150 knockdown cells. The kymograph for WT cell showed 
several diagonal lines indicating high number of motility events. The sh SCR kymograph 
was comparable to the WT kymographs with lot of motility events. The kymograph for 
the sh p150 knockdown cell had lesser number of diagonal lines than the WT implying 
that less motility events happened in the sh p150 knockdown cell.  
Table 5: Mitochondrial motility data in CAD cells 
 WT  
Control cells 
sh SCR 
Transfected cells 
sh p150 
Transfected cells 
Total movements (n) 
644 347 172 
Average number of 
movements/cell 65 66 25 * 
Average Velocity (µ/s) 0.78 ± 0.4 0.86 ± 0.4 0.83 ± 0.4 
Average Distance (µ) 0.94 ± 0.7 1.04 ± 0.7 1.30 ± 1.0 * 
The table shows mitochondrial motility data for control cells Wildtype (WT), sh SCR and for the 
sh p150 knockdown cells.  The data was collected at 72hr post transfection time point. The ‘*’ 
indicates values that were significantly different from the control values, P < 0.01 (Student’s T-
test).  
 
From the kymographs of movies from each condition, I was able to determine the 
direction, run length and velocities of each motility event as well as the total number of 
movements (Table 5).  When compared to the control cells, I found that the average 
number of mitochondrial movements per cell was significantly reduced in the sh p150 
knockdown cells. Because p150 knockdown cells also have reduced dynactin present 
(Fig. 23), it appears most likely that p150 has a normal role in helping with mitochondrial 
movements by functioning as a dynein cargo adaptor and linking dynein to the 
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mitochondria for transport. No significant change was noted in the average velocity of 
mitochondrial movements between the control and the knockdown cells. 
However, I observed an unexpected increase in the average distance travelled by 
the mitochondria in the sh p150 knockdown cells. This was unexpected because dynactin 
has been identified as a processivity enhancer for dynein (Culver-Hanlon et al., 2006) and 
under that model, the loss of dynactin should have lowered the distance mitochondria 
travelled in each motility event. One possibility to explain this discrepancy is that 
dynactin disruption in the knockdown cells might have changed the state where kinesin 
and dynein were equally active to a state where kinesin is predominantly more active. 
This might have altered the active kinesin vs. active dynein ratio and may have decreased 
the number of “tug-of-war” situations between the opposite ended motor proteins (as 
mentioned in the Introduction chapter). Because of the loss of active dynein, kinesin may 
have been then able to run uninhibited for longer distances and resulted in longer 
mitochondrial run lengths as observed in the p150 knockdown cell. An analogy that can 
be used to understand this behavior is a classic ‘tug-of-war’ game with two teams pulling 
on a single rope (mitochondria). When one team (dynein) has less active members (due to 
p150 knockdown), then the other team (kinesin) is more likely to move unopposed as it is 
significantly stronger than the other weakened team (dynein).  
The data observations became much clearer when the data points for each 
mitochondrial movement were plotted in a distance (x-axis) vs. velocity (y-axis) graph 
(Fig, 25). The WT and sh p150 data points were each clustered for the most part at the 
short distances side i.e. on the left area of the graph. Interestingly, I observed that the 
mitochondrial movements at longer distances were predominantly of sh p150 knockdown 
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cells (circled in Fig. 25). This observation correlates with the significant increase found 
in the average distances of sh p150 mitochondrial movements as seen in the Table 5.  
 
Figure 25: Distance vs. Velocity graph of mitochondrial movements 
WT and sh p150 motility events are plotted with distance on x-axis and velocity on y-axis. A 
subset of circle data points (encircled) represent the longest run lengths for the mitochondrial 
movements. 
 
Next, the mitochondrial movements were plotted in a histogram (Fig. 26) of the 
percentage of movements (y-axis) per µm distance intervals (x-axis). I noted that about 
70% of WT mitochondrial movements occurred at shorter distance of ~1µm. For the sh 
p150 knockdown cells, only 50% mitochondrial movements occurred at shorter distances 
under ~1µm. Additionally, for the sh p150 knockdown cells, I saw a corresponding shift 
in the percentage of mitochondrial movements to the longer distance bin intervals 
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(>1µm) compared to the WT mitochondrial movements. Exponential curve fitting of the 
histogram bar graph provided a rationale for the behavior I observed. For WT cells a 
simple exponential decay provides an excellent fit to the data with the best correlation 
factor (R) for the curve equations, indicating that a single uniform probability event 
governs the distance mitochondria moved. Based on the large literature supporting single 
exponential decay fits for single motors, it appear that the WT mitochondria are moved 
by a single motor in CAD cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Histogram of percentage of mitochondrial movements 
The plot shows the distribution of mitochondrial movements in one micron (µm) distance 
intervals. WT and sh p150 data can be fit to single exponential decay curves (black for WT; blue 
for sh p150), with the WT data providing a stronger fit than the sh p150 data (as determined by 
the ‘correlation factor’ R). 
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In contrast, the curve is clearly shifted in sh p150 cells and an exponential decay 
does not fit the observed data as well as for the WT cells. This indicates that some 
additional factors besides a single active motor, are acting on mitochondrial distance 
travelled in p150 knockdown cells. Also, the correlation curve equation explains that 
compared to the WT cell, the mitochondrial movements in sh p150 knockdown cells 
perpetuated longer before disassociating (or decaying) from the microtubule. Hence, this 
supports the observation of the longer mitochondrial run lengths obtained in the sh p150 
knockdown cells. 
 
3.4.2 Effects of dynein inhibition on motility 
Ciliobrevin has the potential to be on an incredibly powerful tool for motility 
studies as it inhibits dynein motor activity in vitro and in vivo (Firestone et al., 2012). I 
decided to utilize this drug as a way to inhibit dynein in CAD cells and record live cell 
movies showing its effect on the mitochondrial motility. There were two clear 
consequences of adding the Ciliobrevin in CAD cells. The first and expected 
consequence was that the mitochondrial motility dropped significantly after adding the 
drug. Live cell movies provided data that was not suitable for generating kymographs and 
hence, further analysis using motility counts was performed. Cells treated with 
Ciliobrevin showed an average number of movements close to 15, which was lesser than 
the average number of movements of 50 in an untreated control cell. The second and 
totally unexpected consequence of Ciliobrevin addition was an immediate change in the 
morphology of vast majority of mitochondria in CAD cells. 
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Figure 27: Effect of Ciliobrevin on mitochondrial motility 
CAD cells with mitochondria labeled using MitoTracker® Green fluorescent dye. Left: a control 
cell with no drug added in which mitochondrial morphology looked normal. Right: a cell with 
Ciliobrevin drug (100µM) added in which the mitochondrial morphology changed significantly. 
Scale bar = 5µm.  
 
Normally mitochondria are long and stretched out with cigar like shape, however, after 
addition of Ciliobrevin mitochondria rounded up into what appear to be larger spheres 
(Fig. 27). Future experiments will be required to further characterize the mitochondrial 
morphology change. 
The unexpected mitochondrial morphology change raises a serious concern on the 
specificity of Ciliobrevin drug in inhibiting the dynein motor function. It is unclear if the 
drop in mitochondrial motility was caused by the mitochondrial morphology change. 
Alternatively, the reverse can be possible: the mitochondria change in morphology could 
No Ciliobrevin With Ciliobrevin 
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be caused by a drop in dynein motility. This second possibility could be due to some 
process where active dynein motors are needed to maintain mitochondria shape. 
However, treatments with microtubule polymerizing drugs (such as nocodazole) that 
prevent dynein activity do not cause such morphology change (Kabashima et al., 2013). 
Another possibility could be that both the events (mitochondrial morphology change and 
motility drop) can occur independent to each other. For example, Ciliobrevin may inhibit 
dynein motor as expected, yet also directly inhibit some other critical ATP sensitive 
protein that plays an important role in maintaining the mitochondrial morphology. 
Hence, due to the non-specific inhibitory effects caused on the mitochondria in 
the cells, Ciliobrevin appears to be a “troublesome” inhibitor. In light of my observation 
with Ciliobrevin, I will not prefer to inhibit dynein function with this approach in future 
experiments.  
3.5 Future directions 
I determined that affecting any one component of the dynein/dynactin motor 
complex does affect the intracellular motility, but in different fashion. In p150 
knockdown cells, the effect of partial loss of dynactin function was observed as a 
decrease in the average number of mitochondrial movements and an increase in the 
mitochondrial run length was seen. 
 The ground work is now set to carry out the second step of the ‘knockdown and 
replacement’ strategy involved in the long term future goal of reducing the endogenous 
dynactin level and expressing an exogenous neurodegeneration linked mutant dynactin. It 
would be exciting to see how the mitochondrial motility of the cell is affected by the 
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exogenous expression of neurodegenerative-linked mutant dynactin. One possibility is 
that mutant dynactin can rescue motility defects by increasing the average number of 
mitochondrial movements in a p150 knockdown-replaced cell. This means that, instead 
of causing transport defects, the mutation in dynactin has a different mechanism of 
causing neurodegeneration. For example, in this case the mutation might be causing 
dynactin to misfold and hence leading to neurodegeneration, even though there is no 
transport defect as it was seen in a dynactin knockdown cell. Alternatively, the mutant 
dynactin can drastically alter the mitochondrial motility parameters in the p150 
knockdown-replaced cells. This would imply that mutations in dynactin lead to transport 
defects and this can be directly linked as a mechanism for causing neurodegeneration by 
such dynactin mutations. 
 
  
 50 
 
CHAPTER 4: MATERIALS AND METHODS 
4.1 N.crassa motility analyses 
 
4.1.1 Vesicle labeling  
N. crassa hyphae were treated with the membrane binding dye called FM® 4-64 
[N-(3-Triethylammoniumpropyl)-4-(6-(4-(Diethylamino) Phenyl) Hexatrienyl) 
Pyridinium Dibromide, (Molecular Probes®, Invitrogen™)]. This dye stains lipid 
membranous vesicles and fluoresces red under proper excitation wavelength on a 
fluorescent microscope. The following steps were followed to label the vesicles with 
FM4-64 dye: 
1. The N.crassa strains (WT and various mutant strains) were grown on a VSM agar 
(Vogel’s minimal media + 2% Sucrose) coated slide and incubated at 28°C for 
16-18 hrs.  
2. FM 4-64 dye (5µM final concentration) was mixed with VSM liquid medium and 
about 20μl was added to the VSM coated slide containing growing hyphae. 
3. A coverslip was added on top of the VSM liquid followed by immediate 
visualization (live cell imaging) on a microscope. 
4.1.2 Live cell imaging 
The microscope used for the N. crassa live cell imaging was an Olympus BX50 
upright microscope with a 100X (1.3 N.A.) oil immersion objective lens. The movies 
were acquired using SPOT software (v3.5.9) on a SPOT RT-SE 18 camera system 
(Diagnostic Instruments). Each time-lapse live cell movie was made with images taken 
every 200 millisecond for a total duration of 30 seconds. A movie stack was comprised of 
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150 frames as five frames were taken per second. Each pixel of the image was 0.13 µm 
across at the magnification used. Between 10 and 15 movies tracking the FM 4-64 
stained vesicles were captured for the N.crassa WT and DHC mutant strains.  
4.2 CAD cell motility analyses 
4.2.1 Cell Culture 
CAD cells were grown in a T75 tissue culture flask with complete CAD medium 
containing DMEM/F12 Nutrient Mix (Gibco®) with Glutamax™ (1%,Gibco®), 
Pen/Strep (1%) and Fetal Bovine Serum ( FBS, 10%). Next, the cells were plated from a 
T75 flask onto a 25mm coverslip (10,000-15,000 cell density) in a six well plate. These 
plated cells were then grown in a FBS free medium so that they extend projections. 
4.2.2 Transfection with knockdown plasmid 
To knockdown the endogenous level of dynactin in CAD cells, the short hairpin 
(sh) plasmids against the external region (3’UTR) of the p150 coding sequence (sh p150) 
were used.  
 
Figure 28: Knockdown sh-plasmid structure 
The knockdown sh plasmid has a shRNA coding sequence against the p150 subunit or a 
scrambled coding sequence for transfection control. The shRNA region is under the control of the 
H1 promoter. The sh plasmid also has a coding sequence for the mCherry red fluorescent protein 
(under the CMV promoter) to indicate transfected cells. 
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For transfection controls, sh plasmids containing a scrambled coding sequence (sh SCR) 
were used. The shRNA expression was under the control H1 promoter (Fig. 28) and the 
plasmid also contained a coding sequence to produce the red fluorescent protein mCherry 
as a reporter signal to indicate transfected cells. 
For the knockdown experiments, the CAD cell coverslips were transfected 24 
hours after plating onto coverslips. The CAD cells were either transfected with a sh p150 
or with a control sh SCR plasmid.  
The following steps were followed for the transfection- 
1. For each coverslip, 100µl of Opti-MEM® reduced serum (Gibco®) was mixed 
with 6µl of X-tremeGENE HP DNA Transfection Reagent (Roche) in a tube and 
incubated for 10 minutes. 
2. Next, sh p150 or sh SCR plasmid DNA (2µg/coverslip) was added to the tube and 
incubated for 15 minutes. 
3. After the incubation was complete, the plasmid DNA mix was added to 2ml of 
FBS free CAD medium and gently mixed. 
4. The old media was removed from the well containing CAD cells on a coverslip, 
and then the plasmid DNA mix was added. The cells were incubated overnight at 
37°C in a standard humidified CO2 incubator. 
5. The next morning, the media over the coverslip was replaced with 2ml of fresh 
FBS free CAD medium. 
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4.2.3 Mitochondria labeling  
MitoTracker® Green (Molecular Probes®, Invitrogen™) was used to label and 
track mitochondria in CAD cells. The mitochondria labeling steps were as follow: 
1. Media was removed from a well containing a coverslip and the CAD cells were 
gently rinsed with ~ 1.5 ml PBS (0.01 M phosphate buffer, 0.0027 M KCl and 
0.137 M NaCl, Sigma). 
2. After removing the PBS, freshly prepared 1ml of   MitoTracker Green (50nM) in 
FBS free CAD media was added and incubated at 37°C for 30 minutes. 
3. After the incubation, the MitoTracker Green containing media was removed from 
the coverslip and the cells were again gently rinsed with ~1.5ml PBS. 
4. The coverslip was removed from the well and placed in a pre-warmed live cell 
chamber. 
5. Warm 1.5ml FBS free CAD media was added gently on to the cells and a fresh 
coverslip was put on top to prepare a live cell chamber for imaging. 
4.2.4 Ciliobrevin treatment 
CAD cells were treated with a 100µM Ciliobrevin drug (Trade name: 
Calbiochem, EMD Millipore) to inhibit dynein function. A Ciliobrevin stock solution 
(10mM) was prepared in DMSO. Ciliobrevin drug treatment steps were as follows: 
1. Media was removed from CAD cells and the cells were gently rinsed with ~ 1.5 
ml PBS. 
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2. After removing the PBS, freshly made 1ml of the 50nM MitoTracker Green 
dilution with FBS free CAD media was added and incubated at 37°C for 30 
minutes. 
3. After the incubation period, the MitoTracker Green solution was removed from 
the coverslip and the cells were again gently rinsed with ~1.5ml PBS. 
4. The coverslip was removed from the well and placed in a pre-warmed live cell 
chamber. 
5. Warm 1.5ml FBS free CAD media with 15µl of Ciliobrevin stock solution 
(10mM) was added gently on to the cells. 
6. A fresh coverslip was put on top to prepare the live cell chamber of CAD cells for 
imaging. 
4.2.5 Live cell imaging 
The mitochondrial motility movies were acquired by the ‘stream acquisition’ 
function of the Metamorph software (Molecular Devices, CA) using an Evolve™ 512 
EMCCD camera (Photometrics® System). The microscope used was a Nikon® Eclipse 
Ti inverted fluorescent microscope with a CFI Apo TIRF 100X/1.49 oil immersion 
objective lens with an additional 1.5X magnification adaptor. Each live cell movie 
prepared was a stack of 500 frames, with 10 frames taken per second for a total duration 
of 50 seconds. Each pixel of the image was 0.11 μm across at the magnification used. 
Numerous movies of mitochondrial motility under the p150 knockdown and control 
conditions were recorded and repeated at least on three separate days. 
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4.3 Kymograph and data analyses 
The analysis of live cell motility movies for N. crassa and CAD cells were carried out 
using Metamorph Software (Molecular Devices, CA). On a movie frame (Fig. 29 I), a 
region line ‘A to B’ was drawn to track the path of the moving cargoes (FM® 4-64 
labeled vesicles or mitochondria). The region line ‘AB’ was then generated into a 
kymograph (Fig. 29 II). A kymograph is a distance (x-axis) vs. time (y-axis) graph that 
showed the position of all fluorescent signals (cargo) during the course of the movie. So, 
if there is a cargo that did not move during the course of the movie, then a vertical line 
(Fig.29 II, blue line) was generated on a kymograph representing that cargo’s stationary 
motility pattern. That vertical line had a constant distance that did not change with time 
on the kymograph. However, if a cargo moved, then the fluorescent signal generated a 
diagonal line (Fig.29 II, yellow line) that showed a distance displacement with respect to 
time. Hence, the vertical lines on the kymographs represented the stationary cargoes and 
the diagonal lines with slopes represented the moving cargoes.  
Next, I performed further analyses to obtain data on diagonal lines from the 
kymographs (Fig. 29 III). The width (in pixels) of the diagonal lines was measured from 
the kymograph and entered in a customized excel sheet. The excel sheet had formulae 
based on the pixels/µm value of the microscope to generate the respective real distance 
(in µm) of the cargo. Similarly, the height (in pixels) of the diagonal lines was measured 
and gave a value of the real time duration (in seconds) in the excel sheet. The real 
distance (µm) was divided by the real time (seconds) to generate the real velocities 
(µm/seconds) of the cargo. 
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Figure 29: Kymograph generation and analysis 
Panel I: A region line ‘AB’ is drawn on a movie frame to track the movement of cargo (blue and yellow circles). Panel II: Kymograph 
(distance vs. time graph) is generated from the region line ‘AB’. The blue vertical line represents stationary cargo and the yellow line 
represents stationary-movement-stationary motility pattern of a moving cargo. Panel III: The height, width and slope of the diagonal line can 
give information on the time duration (seconds), distance (µm) and the velocity (µm/sec) of the moving cargo. 
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Also, the angle of the slope provided information on the direction of the cargo 
movements. The angle specified if the cargo was moving from the cell center to the cell 
periphery or vice versa. This slope determination helped in generating the percentage of 
movements happening in the inward vs. outward directions. 
Also, the growth rate of N. crassa hyphal tip was calculated by measuring the 
starting point of the tip (in pixels) at the beginning of the movie and the final point of the 
grown tip at the end of the movie. Next, these distances were converted to real distances 
(in µm) and the distance of the initial hyphal tip length was subtracted for the final 
hyphal tip length. The length difference (in µm) was divided by the duration of the movie 
that is 30 seconds to get the rate of growth (µm/seconds) of the hyphal tip. 
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